Target Price | $726.00 |
Price | $521.84 |
Potential | 39.12% |
Number of Estimates | 21 |
21 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $726.00. This is 39.12% higher than the current stock price. The highest price target is $940.00 80.13% , the lowest is $504.00 3.42% . | |
A rating was issued by 27 analysts: 20 Analysts recommend Regeneron Pharmaceuticals to buy, 6 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 39.12% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
22 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $13.4b . This is 5.08% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $14.1b 0.03% , the lowest is $12.7b 10.06% .
This results in the following potential growth metrics:
2024 | $14.2b | 8.27% |
---|---|---|
2025 | $13.4b | 5.86% |
2026 | $14.3b | 6.76% |
2027 | $15.7b | 9.96% |
2028 | $16.7b | 6.43% |
2029 | $17.9b | 7.00% |
9 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.3b . This is 5.43% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $5.3b 15.65% , the lowest is $3.5b 23.68% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.7b | 1.17% |
---|---|---|
2025 | $4.3b | 8.28% |
2026 | $5.0b | 15.82% |
2027 | $5.9b | 18.78% |
2028 | $6.2b | 3.97% |
2029 | $6.9b | 12.20% |
2024 | 33.10% | 8.72% |
---|---|---|
2025 | 32.25% | 2.57% |
2026 | 34.99% | 8.50% |
2027 | 37.79% | 8.00% |
2028 | 36.92% | 2.30% |
2029 | 38.71% | 4.85% |
11 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $3.3b . This is 27.40% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.1b 8.35% , the lowest is $2.4b 45.99% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.4b | 11.61% |
---|---|---|
2025 | $3.3b | 25.98% |
2026 | $3.6b | 10.21% |
2027 | $4.3b | 20.65% |
2028 | $5.0b | 14.33% |
2029 | $5.6b | 12.08% |
2024 | 31.07% | 3.08% |
---|---|---|
2025 | 24.43% | 21.37% |
2026 | 25.22% | 3.23% |
2027 | 27.67% | 9.71% |
2028 | 29.73% | 7.44% |
2029 | 31.14% | 4.74% |
11 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $30.19 . This is 25.38% lower than earnings per share in the financial year 2024. The highest EPS forecast is $38.11 5.81% , the lowest is $22.46 44.49% .
This results in the following potential growth metrics and future valuations:
2024 | $38.34 | 10.27% |
---|---|---|
2025 | $30.19 | 21.26% |
2026 | $33.27 | 10.20% |
2027 | $40.14 | 20.65% |
2028 | $45.90 | 14.35% |
2029 | $51.44 | 12.07% |
Current | 12.90 | 56.91% |
---|---|---|
2025 | 17.29 | 34.05% |
2026 | 15.68 | 9.31% |
2027 | 13.00 | 17.09% |
2028 | 11.37 | 12.54% |
2029 | 10.14 | 10.82% |
Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 3.79 and an P/S ratio of 4.21 .
This results in the following potential growth metrics and future valuations:
Current | 3.60 | 54.08% |
---|---|---|
2025 | 3.79 | 5.33% |
2026 | 3.55 | 6.33% |
2027 | 3.23 | 9.06% |
2028 | 3.04 | 6.04% |
2029 | 2.84 | 6.55% |
Current | 4.00 | 52.58% |
---|---|---|
2025 | 4.21 | 5.35% |
2026 | 3.95 | 6.33% |
2027 | 3.59 | 9.06% |
2028 | 3.37 | 6.04% |
2029 | 3.15 | 6.55% |
Regeneron Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Jun 09 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Jun 05 2025 |
Citigroup |
Buy
➜
Buy
|
Unchanged | Jun 02 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jun 02 2025 |
BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Jun 02 2025 |
Wells Fargo |
Overweight
➜
Equal-Weight
|
Downgrade | May 30 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | May 27 2025 |
Analyst Rating | Date |
---|---|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Jun 09 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Jun 05 2025 |
Unchanged
Citigroup:
Buy
➜
Buy
|
Jun 02 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jun 02 2025 |
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Jun 02 2025 |
Downgrade
Wells Fargo:
Overweight
➜
Equal-Weight
|
May 30 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
May 27 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.